HOUSTON, July 28, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that the Company's new cGMP manufacturing facility in Houston, TX, located near the George Bush Intercontinental Airport, is fully operational. The facility will manufacture Marker's MultiTAA-specific T cell products for the Company's Phase 2 acute myeloid leukemia (AML) trial as well as future hematological and solid tumor trials, in addition to producing the potential commercial supply of any approved products.
Search / 90 results found Showing: 1-10 of 90
Dua Lipa has addressed her 'Levitating' collaborator DaBaby's "insensitive" remarks about HIV/AIDs at Rolling Loud Miami.
(The Center Square) – The U.S. Centers for Disease Control and Prevention changed course Tuesday, reversing its previous COVID-19 guidance by urging Americans to wear masks, regardless of their vaccination status. Critics quickly denounced the reversal, saying it undermines vaccine confidence.
Fort Bend County is trying to find a way to get a hold on the widespread Delta variant of COVID-19, which is causing cases to go up despite th…
Emmy Rossum's baby daughter has coronavirus antibodies.
HOUSTON and SINGAPORE, July 26, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced that internationally renowned scientist and medical oncologist, Dr. Thomas J Lynch, Jr, MD, has been appointed to its Board as a Non-Executive Director, effective immediately.
Accepting the COVID-19 vaccine is the "compassionate thing to do", according to Olivia Rodrigo.